Embracing Similarity. Ensuring Safety. Delivering Confidence.
As global demand for biosimilars grows, regulatory expectations and pharmacovigilance (PV) complexity continue to rise. At PrimeVigilance, we provide end-to-end, product-lifecycle pharmacovigilance solutions purpose-built for biosimilar development, approval, and post-marketing safety.
Our biosimilars unit offers deep therapeutic knowledge, regulatory insight, and operational precision to support global compliance, real-world safety monitoring, and market differentiation. From clinical trial support to lifecycle maintenance and global reporting, we deliver a flexible and scalable PV model tailored to biosimilar challenges.
With proven excellent quality and compliance track record, our team of experts ensures you don’t just meet requirements—you gain a trusted partner to help unlock your product’s full potential.
Global Reach, Local Insight
Our operational teams in North America, Europe, Japan, and India provide true global oversight with local PV network coverage in 160+ countries. Whether you’re preparing a submission or scaling globally, our experts understand the nuances of regional and international biosimilar frameworks.
Expertise in Biosimilars
- Business-unit model ensures portfolio-specific focus and therapeutic specialization across services
- Managing complex partner management, training, audit frameworks, and safety strategies
- Proven record of providing services that ensure rigorous safety standard
- 50% of our PMs have hands-on biosimilar/generic experience
- Tailored PV roadmaps to facilitate marketing authorization (MA) or transfer of MAs and lifecycle maintenance PVIntegrate™ lifecycle strategy
Track Record that Builds Trust
+
years of biosimilar and hybrid PV leadership
+
global clients, including strategic support for long-term product portfolios
%
of clients partner with us for over 5 years
%
customer satisfaction (recognized for consistent, compliant delivery)
"Safety for Biosimilars: Strategic Pharmacovigilance Solutions"
Friday, October 17, 2025
In this webinar, the featured speakers will examine the critical aspects of bringing biosimilars to market and ensuring their ongoing safety and efficacy. They will also explore how pharmaceutical companies can develop effective and scalable pharmacovigilance systems that address the distinct requirements of biosimilar products while maintaining cost-efficiency. Practical solutions for overcoming the most pressing challenges in biosimilar safety management will also be highlighted.
As part of the Ergomed Group, PrimeVigilance connects biosimilar clients with full-spectrum services across pharmacovigilance, clinical development, medical information, and regulatory consulting.
Whether you’re navigating a global PASS study, planning for lifecycle maintenance, or addressing regulatory challenges in oncology, immunology, or rheumatology, we bring unmatched cross-functional strength and biosimilar-specific insight.
